BACKGROUND: Asthma severity is reflected in many aspects of the disease, including impairment and future risks, particularly for exacerbations. According to the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, however, to assess more comprehensively the severity of asthma the level of current treatment needed to maintain a level of control should be included. OBJECTIVE: Development and validation of a new instrument, the Composite Asthma Severity Index (CASI), which can quantify disease severity by taking into account impairment, risk, and the amount of medication needed to maintain control. At present, there is no instrument available to measure and assess the multidimensional nature of asthma. METHODS:Twenty-six established asthma investigators, who are part of the National Institutes of Health-supported Inner City Asthma Consortium, participated in a modified Delphi consensus process to identify and weight the dimensions of asthma. Factor analysis was performed to identify independent domains of asthma by using the Asthma Control Evaluation trial. CASI was validated by using the Inner City Anti-IgE Therapy for Asthma trial. RESULTS:CASI scores include 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations. At Asthma Control Evaluation trial enrollment, CASI ranged from 0 to 17, with a mean of 6.2. CASI was stable, with minimal change in variance after 1 year of treatment. In external validation, CASI detected a 32% larger improvement than did symptoms alone. CONCLUSION:CASI retained its discriminatory ability even with low levels of symptoms reported after months of guidelines-directed care. Thus, CASI has the ability to determine the level of asthma severity and provide a composite clinical characterization of asthma. Published by Mosby, Inc.
RCT Entities:
BACKGROUND:Asthma severity is reflected in many aspects of the disease, including impairment and future risks, particularly for exacerbations. According to the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, however, to assess more comprehensively the severity of asthma the level of current treatment needed to maintain a level of control should be included. OBJECTIVE: Development and validation of a new instrument, the Composite Asthma Severity Index (CASI), which can quantify disease severity by taking into account impairment, risk, and the amount of medication needed to maintain control. At present, there is no instrument available to measure and assess the multidimensional nature of asthma. METHODS: Twenty-six established asthma investigators, who are part of the National Institutes of Health-supported Inner City Asthma Consortium, participated in a modified Delphi consensus process to identify and weight the dimensions of asthma. Factor analysis was performed to identify independent domains of asthma by using the Asthma Control Evaluation trial. CASI was validated by using the Inner City Anti-IgE Therapy for Asthma trial. RESULTS: CASI scores include 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations. At Asthma Control Evaluation trial enrollment, CASI ranged from 0 to 17, with a mean of 6.2. CASI was stable, with minimal change in variance after 1 year of treatment. In external validation, CASI detected a 32% larger improvement than did symptoms alone. CONCLUSION: CASI retained its discriminatory ability even with low levels of symptoms reported after months of guidelines-directed care. Thus, CASI has the ability to determine the level of asthma severity and provide a composite clinical characterization of asthma. Published by Mosby, Inc.
Authors: William W Busse; Wayne J Morgan; Peter J Gergen; Herman E Mitchell; James E Gern; Andrew H Liu; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Jacqueline A Pongracic; James F Chmiel; Suzanne F Steinbach; Agustin Calatroni; Alkis Togias; Katherine M Thompson; Stanley J Szefler; Christine A Sorkness Journal: N Engl J Med Date: 2011-03-17 Impact factor: 91.245
Authors: R Evans; P J Gergen; H Mitchell; M Kattan; C Kercsmar; E Crain; J Anderson; P Eggleston; F J Malveaux; H J Wedner Journal: J Pediatr Date: 1999-09 Impact factor: 4.406
Authors: Wayne J Morgan; Ellen F Crain; Rebecca S Gruchalla; George T O'Connor; Meyer Kattan; Richard Evans; James Stout; George Malindzak; Ernestine Smartt; Marshall Plaut; Michelle Walter; Benjamin Vaughn; Herman Mitchell Journal: N Engl J Med Date: 2004-09-09 Impact factor: 91.245
Authors: M Kattan; H Mitchell; P Eggleston; P Gergen; E Crain; S Redline; K Weiss; R Evans; R Kaslow; C Kercsmar; F Leickly; F Malveaux; H J Wedner Journal: Pediatr Pulmonol Date: 1997-10
Authors: Leonard B Bacharier; Robert C Strunk; David Mauger; Deborah White; Robert F Lemanske; Christine A Sorkness Journal: Am J Respir Crit Care Med Date: 2004-06-01 Impact factor: 21.405
Authors: Elizabeth C Matsui; Matthew Perzanowski; Roger D Peng; Robert A Wise; Susan Balcer-Whaley; Michelle Newman; Amparito Cunningham; Adnan Divjan; Mary E Bollinger; Shuyan Zhai; Ginger Chew; Rachel L Miller; Wanda Phipatanakul Journal: JAMA Date: 2017-03-14 Impact factor: 56.272
Authors: Wanda Phipatanakul; Petros Koutrakis; Brent A Coull; Choong-Min Kang; Jack M Wolfson; Stephen T Ferguson; Carter R Petty; Mihail Samnaliev; Amparito Cunningham; William J Sheehan; Jonathan M Gaffin; Sachin N Baxi; Peggy S Lai; Perdita Permaul; Liming Liang; Peter S Thorne; Gary Adamkiewicz; Kasey J Brennan; Andrea A Baccarelli; Diane R Gold Journal: Contemp Clin Trials Date: 2017-06-12 Impact factor: 2.226
Authors: David B Kantor; Molly C McDonald; Nicole Stenquist; Blake J Schultz; Craig D Smallwood; Kyle A Nelson; Wanda Phipatanakul; Joel N Hirschhorn Journal: Am J Respir Crit Care Med Date: 2016-12-15 Impact factor: 21.405
Authors: Torie Grant; Charles Aloe; Matthew Perzanowski; Wanda Phipatanakul; Mary E Bollinger; Rachel Miller; Elizabeth C Matsui Journal: J Allergy Clin Immunol Pract Date: 2016-12-05
Authors: Daniel J Jackson; Leonard B Bacharier; Agustin Calatroni; Michelle A Gill; Jack Hu; Andrew H Liu; Lisa M Wheatley; James E Gern; Rebecca S Gruchalla; Gurjit K Khurana Hershey; Meyer Kattan; Carolyn M Kercsmar; Haejin Kim; George T O'Connor; Shilpa Patel; Jacqueline A Pongracic; Robert A Wood; William W Busse Journal: J Allergy Clin Immunol Date: 2020-01-28 Impact factor: 10.793
Authors: Ronald L Sorkness; Edward M Zoratti; Meyer Kattan; Peter J Gergen; Michael D Evans; Cynthia M Visness; Michelle Gill; Gurjit K Khurana Hershey; Carolyn M Kercsmar; Andrew H Liu; George T O'Connor; Jacqueline A Pongracic; Dinesh Pillai; Christine A Sorkness; Alkis Togias; Robert A Wood; William W Busse Journal: J Allergy Clin Immunol Date: 2017-11-14 Impact factor: 10.793
Authors: Rebecca Z Krouse; Christine A Sorkness; Jeremy J Wildfire; Agustin Calatroni; Rebecca Gruchalla; Gurjit K Khurana Hershey; Meyer Kattan; Andrew H Liu; Melanie Makhija; Stephen J Teach; Joseph B West; Robert A Wood; Edward M Zoratti; Peter J Gergen Journal: J Allergy Clin Immunol Date: 2016-10-12 Impact factor: 10.793